Gepirone Selective 5-HT1A Agonism for Sexual Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of reliable medicinal recommendations for treating sexual disorders, particularly in females, and existing antidepressants often exacerbate sexual side effects, necessitating a treatment that can effectively address hypoactive sexual desire, orgasmic, and arousal disorders in both short-term and long-term therapies.
Innovation Solution
Gepirone, a drug initially investigated for its antidepressant effects, is administered in effective amounts for the improvement of sexual drive and treatment of sexual dysfunction disorders, including hypoactive sexual desire and orgasmic disorders, as a short-term or long-term therapy, either alone or in combination with other pharmaceutical auxiliaries, providing a pharmaceutical composition for oral, parenteral, or topical administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressant drugs with serotonin reuptake inhibiting effect are used to treat depression, then depressive symptoms are improved, but sexual dysfunction occurs as a side effect
Solution Approach 1:
The patent extracts the harmful sexual dysfunction side effect from the antidepressant treatment by using gepirone, a selective 5-HT1A receptor partial agonist, which provides antidepressant effects without the sexual dysfunction associated with traditional serotonin reuptake inhibitors. This separates the therapeutic benefit from the adverse effect.
Solution Approach 2:
The patent changes the pharmacological parameter from non-selective serotonin reuptake inhibition to selective 5-HT1A receptor partial agonism. Gepirone has high affinity for 5-HT1A receptors with minimal affinity for other serotonin receptors, fundamentally changing the mechanism of action to eliminate sexual dysfunction while maintaining antidepressant efficacy.
2Duration of action of stationary object
If traditional antidepressants are used for long-term therapy, then depression is managed, but sexual dysfunction persists and may worsen
Solution Approach 1:
The patent converts the previously harmful long-term use of antidepressants into a beneficial treatment by using gepirone, which provides sustained antidepressant effects without the chronic sexual dysfunction. The selective 5-HT1A agonism mechanism transforms the long-term treatment profile from harmful to beneficial regarding sexual function.
3Speed
If fast-acting pharmaceutical formulations are used for as-needed treatment of premature ejaculation, then immediate effect is achieved, but they are not suitable for long-term therapy of sexual disorders
Solution Approach 1:
The patent creates a universal treatment approach with gepirone that serves multiple functions: it can be used for long-term management of various sexual disorders including hypoactive sexual desire, arousal disorders, and orgasmic disorders in both men and women, as well as for premature ejaculation, eliminating the need for different formulations for different indications.
Data Source
AI summary
The present invention relates to a method of treatment of sexual dysfunction e.g. female sexual disfunction by administering to a person in need of treatment an effective amount of gepirone as either a short-term or a long-term therapy.